InSightec

What InSightec does

InSightec Ltd. is an Israel-based, privately held medical device company founded in 1999 that develops and commercializes MR-guided focused ultrasound (MRgFUS) systems for incisionless neurosurgery. Its core product platform, the Exablate family (Exablate Neuro, Exablate Prime, and the international ExAblate 4000), uses high-intensity focused ultrasound beams focused through the intact skull to thermally ablate targets in the thalamus and other deep brain structures, with real-time MRI providing sub-millimeter treatment planning, continuous thermometry, and intra-procedural feedback. The system is FDA-approved for medication-refractory essential tremor and, as of July 2025, for staged bilateral pallidothalamic tractotomy in advanced Parkinson's disease, with more than 30,000 patients treated across 160+ installed systems worldwide.

The company generates revenue through capital equipment sales of Exablate systems to hospitals and treatment centers, supported by service contracts and per-procedure economics billed under CPT code 0398T, with reimbursement secured from Medicare in all 50 US states and major private insurers including Aetna, CIGNA, and Anthem. Distribution is hybrid: direct field sales in core markets combined with a network of regional channel partners and a Fosun-Insightec joint venture in China, backed by regional headquarters in Miami (Americas), Frankfurt (EMEA), Tokyo (Japan/APAC), and Shanghai (China). In December 2025, InSightec spun out Lotus Neuro, a clinical-stage biotechnology company focused on using low-frequency focused ultrasound to enable drug delivery across the blood-brain barrier, initially in glioblastoma and diffuse midline gliomas, while InSightec retained the device innovation and commercialization business. The company has raised over $900M in cumulative equity and debt funding across multiple rounds, including a $150M Series G led by Fidelity Management & Research Company in June 2024 and a $200M credit facility from Perceptive Advisors and The Community Fund in 2022.

Name

InSightec

Legal name

INSIGHTEC Ltd.

Website

https://insightec.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

InSightec is an Israel-based medical device company that develops MR-guided focused ultrasound (Exablate Neuro/Prime) systems for incisionless neurosurgical treatment of essential tremor and Parkinson's disease, sold to hospitals and treatment centers globally with 160+ systems and 30,000+ patients treated.

Ownership category

akta.pro rank

Product category

Therapeutic Medical Devices (MR-guided Focused Ultrasound Systems)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

Keywords

• MR-guided focused ultrasound
• Incisionless neurosurgery
• Medical imaging devices
• Essential tremor treatment
• Parkinson's disease therapy

Headquarters

HQ city

Tirat Carmel

HQ country

Israel

HQ region

Middle East

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Capital Equipment Sales: Insightec generates revenue primarily through the sale and placement of Exablate focused ultrasound systems to hospitals and treatment centers. Systems are installed at medical facilities globally where procedures are performed on patients.
2. Treatment Procedures: Hospitals and treatment centers bill for focused ultrasound procedures using CPT code 0398T. Insurance coverage includes Medicare in all 50 states and private insurers including Aetna, CIGNA, and Anthem.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

InSightec develops, manufactures, and commercializes the Exablate MR-guided focused ultrasound (MRgFUS) platform, an FDA-approved medical device that enables incisionless neurosurgery for medication-refractory essential tremor and tremor-dominant Parkinson's disease. Hospitals and treatment centers purchase the Exablate systems and use them to perform outpatient thalamotomy procedures with sub-millimeter precision, real-time MRI guidance, and continuous temperature monitoring.

Product overview

InSightec offers a focused ultrasound technology platform centered around the Exablate product line. The flagship Exablate Prime is the current-generation MR-guided focused ultrasound system for incisionless neurosurgery, while Exablate Neuro serves as the FDA-approved indication-specific branding for essential tremor and Parkinson's disease treatment. The ExAblate 4000 is the underlying device platform (known as Exablate Neuro internationally). The company has also spun out Lotus Neuro to advance focused ultrasound for drug delivery across the blood-brain barrier. The platform uses MRI guidance for real-time treatment planning, temperature monitoring, and sub-millimeter precision targeting, enabling outpatient treatment of movement disorders without surgical incisions.

Differentiator

Problem solved

Functional benefit

Brands

• Exablate: MR-guided focused ultrasound platform for incisionless neurosurgery treatment
• Exablate Neuro
• Exablate Prime
• ExAblate 4000

Products and services

• Exablate Prime MR-guided focused ultrasound platform for incisionless neurosurgery, enabling precise treatment of essential tremor and tremor-dominant Parkinson's disease with real-time MRI guidance, sub-millimeter precision, and same-day outpatient treatment. Sold to hospitals and treatment centers.
• Exablate Neuro FDA-approved MR-guided focused ultrasound system specifically designed for treating movement disorders including essential tremor and Parkinson's disease through incisionless thalamotomy procedures. Sold to hospitals, neurosurgeons, and neurologists.
• ExAblate 4000 MR-guided focused ultrasound treatment device that enables incisionless treatment without craniotomy or implants by focusing ultrasound through the skull to treat tremor-causing neural circuits in the thalamus. Sold to Japanese hospitals and treatment centers.

Quantifiable outcome

• 66.8% improvement in motor complications for Parkinson's disease patients
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Florida Atlantic University (FAU)coreStrategic or Co-development Partner · 6 February 2026FAU's NeuroInnovate Center partners with Insightec to advance focused ultrasound treatments for Alzheimer's and Parkinson's diseases. $1 million funding supports the center. FAU unveiled world's first integrated MRI and focused ultrasound research platform with Insightec technology.
• Lotus NeurocoreStrategic or Co-development Partner · 17 December 2025Insightec spun out Lotus Neuro, a clinical-stage biotechnology company advancing brain-targeted therapeutics using precision, low-frequency focused ultrasound to enable drug delivery across the blood-brain barrier. Led by former Insightec CSIO Arjun (JJ) Desai. Insightec retains device innovation business while collaborating with Lotus on platform integration.
• GE HealthcarecoreTechnology or Integration · 15 October 2025Equipment supplier for FAU's integrated MRI and focused ultrasound research platform. Exablate Prime has expanded compatibility with GE Healthcare MR systems along with Philips and Siemens systems.
• Fosun-Insightec Medical Technology Co. LtdcoreChannel Partner/ Reseller/ DistributorAuthorized distributor in China (Room 710 and 711, 7/F, Building 1, No. 83 Yejiazhai Road, Putuo District, Shanghai, China). Distributes Exablate focused ultrasound systems in the Chinese market.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic plc: Medtronic is the dominant manufacturer of deep brain stimulation (DBS) systems for movement disorders including essential tremor and Parkinson's disease. It is a direct therapeutic competitor to InSightec for the same patient population, but uses an implantable neurostimulator approach rather than an incisionless modality.
• Stryker Corporation: Stryker is a broad neurosurgical and spine equipment incumbent, including navigation systems and surgical tools used in neurosurgery suites. As the acquirer of MAKO Surgical (where InSightec CEO Maurice Ferré previously led), Stryker is both an industry peer and a relevant comparable for capital equipment commercialization in neurosurgery.
• Boston Scientific Corporation: Boston Scientific offers the Vercise DBS system for Parkinson's disease and essential tremor, positioning it as a competing modality for the same medication-refractory movement-disorder patients that InSightec targets. It is a broad incumbent neuromodulation player with overlapping clinical use cases.
• Abbott Laboratories: Abbott's neuromodulation business (formerly St. Jude Medical) offers the Infinity DBS system for movement disorders. As one of three major DBS manufacturers, it competes for the same clinical patient population as InSightec's Exablate, though through implantable pulse generator technology rather than focused ultrasound.
• Elekta AB: Elekta manufactures the Leksell Gamma Knife system for stereotactic radiosurgery of brain targets, historically used to treat tremor and other functional disorders. It competes with InSightec for hospital neuroscience capital budgets, though Gamma Knife uses radiation rather than focused ultrasound.

Others

• GE Healthcare: GE Healthcare is both a long-standing InSightec shareholder and the supplier of compatible MRI systems used alongside Exablate. It is an enabling partner and ecosystem participant rather than a direct competitor, but its MRI scanner footprint materially affects InSightec's addressable market for system sales.

Direct peers

• EDAP TMS SA: EDAP TMS manufactures the Focal One and Ablatherm high-intensity focused ultrasound (HIFU) devices for prostate cancer and other urological applications. Comparable as a commercial-stage focused ultrasound therapy company selling capital equipment into hospitals globally, though focused on urology rather than neurosurgery.
• Profound Medical Corp. Profound Medical develops the TULSA-PRO and Sonalleve MR-guided focused ultrasound systems for incisionless prostate and uterine fibroid ablation. It is the closest direct peer to InSightec in MR-guided focused ultrasound therapy, addressing a different anatomical indication but using the same core imaging-and-ultrasound integration architecture.
• Chongqing Haifu Medical Technology: Haifu is a China-based pioneer in clinical focused ultrasound ablation (HIFU) systems used across multiple indications including uterine fibroids, liver, and bone tumors. It is a direct technology peer in the focused ultrasound therapy space, although it competes primarily in Asian markets and non-neurological indications.

Emerging players

• Brainlab AG: Brainlab develops image-guided surgery and neurosurgical navigation platforms used in operating rooms worldwide. It is adjacent to InSightec's MR-guidance workflow and competes for hospital neurosurgery capital budgets, though Brainlab's primary offering is software and navigation rather than focused ultrasound ablation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/focusultrasound
• YouTubeyoutube.com/channel/UCFKMAN-01TyFr-t6KuWlHUg?sub_confirmation=1
• Facebookfacebook.com/47871279106
• LinkedInlinkedin.com/company/insightec

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InSightec